Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Effects of MIND Diet on Brain Fog, Stress, and Sleep Quality in Young Adults (Young Mind)

19 novembre 2026 aggiornato da: Halic University

The Effect of a MIND Diet-Based Nutritional Intervention on Brain Fog, Perceived Stress, Sleep Quality, and Selected Biochemical Findings in Young Adults

This study aims to evaluate the effects of a MIND diet-based nutritional intervention on brain fog, perceived stress, sleep quality, and selected biochemical parameters in young adults. It will also compare the effects of the MIND diet with those of the Mediterranean diet and usual dietary habits.

The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) is a dietary pattern that combines elements of the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diets. It emphasizes the consumption of green leafy vegetables, other vegetables, berries, nuts, whole grains, legumes, fish, poultry, and olive oil, while limiting foods high in saturated fat, processed foods, and sweets. The Mediterranean diet similarly emphasizes plant-based foods, olive oil, whole grains, legumes, vegetables, fruits, nuts, and fish.

Young adults aged 18-35 years who meet the study eligibility criteria will be included. Participants will be randomly assigned to one of three groups: a MIND diet intervention group, a Mediterranean diet intervention group, or a control group.

Participants in the MIND diet group will receive nutritional guidance and follow a MIND diet-based dietary plan for 12 weeks. Participants in the Mediterranean diet group will receive nutritional guidance and follow a Mediterranean diet-based dietary plan for the same period. Participants in the control group will continue their usual dietary habits without receiving a structured dietary intervention during the study period.

Assessments will be conducted at baseline and at the end of the 12-week intervention. These assessments will include brain fog, perceived stress, sleep quality, dietary intake, and anthropometric measurements. Brain fog, perceived stress, and sleep quality will be evaluated using standardized assessment questionnaires. Dietary intake and adherence to the assigned dietary patterns will also be monitored throughout the intervention.

Selected biochemical parameters, including fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, liver enzymes, uric acid, urea, and creatinine, will be assessed through blood samples.

The study will investigate whether following the MIND or Mediterranean dietary pattern for 12 weeks is associated with changes in brain fog, perceived stress, sleep quality, and selected biochemical parameters in young adults. The findings may contribute to a better understanding of the relationship between dietary patterns and cognitive, psychological, sleep-related, and metabolic health.

Panoramica dello studio

Descrizione dettagliata

### Detailed Description

The MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet is a dietary pattern developed by combining elements of the Mediterranean diet and the Dietary Approaches to Stop Hypertension (DASH) diet. It emphasizes foods that may support brain and metabolic health, including green leafy vegetables, other vegetables, berries, nuts, whole grains, legumes, fish, and poultry, while limiting the consumption of foods high in saturated fat, processed foods, sweets, and fried foods.

The Mediterranean diet is characterized by a high intake of vegetables, fruits, legumes, whole grains, nuts, seeds, and olive oil, with regular consumption of fish and moderate consumption of other animal-based foods. Both dietary patterns emphasize minimally processed, nutrient-dense foods and a balanced dietary approach.

This study is designed as a 12-week, randomized, parallel-group, three-arm interventional trial involving young adults aged 18-35 years. The study will compare the effects of a MIND diet-based nutritional intervention and a Mediterranean diet-based nutritional intervention with a control group that will maintain its usual dietary habits.

Participants assigned to the MIND diet group will receive individualized nutritional counseling and a dietary plan based on MIND diet principles. The intervention will emphasize the regular consumption of green leafy vegetables, other vegetables, berries, nuts, legumes, whole grains, fish, and poultry, while encouraging the limitation of foods associated with lower adherence to the MIND dietary pattern.

Participants assigned to the Mediterranean diet group will receive individualized nutritional counseling and a dietary plan based on Mediterranean diet principles. The intervention will emphasize vegetables, fruits, legumes, whole grains, olive oil, nuts, seeds, and fish as important components of daily and weekly food consumption.

Dietary plans will be individualized according to participants' age, sex, physical activity level, and estimated energy requirements. Participants in both intervention groups will receive nutritional guidance throughout the 12-week study period. Dietary adherence and food consumption will be monitored at 15-day intervals using dietary records, including three-day food consumption records, and adherence assessments.

Participants in the control group will not receive a structured dietary intervention and will be asked to maintain their usual dietary habits during the study period.

Baseline assessments will be performed before the dietary interventions begin. At the end of the 12-week intervention, the assessments will be repeated to evaluate changes over time.

The primary areas of assessment include brain fog, perceived stress, and sleep quality. Brain fog will be assessed using the Brain Fog Scale, perceived stress using the Perceived Stress Scale (PSS-10), and sleep quality using the Pittsburgh Sleep Quality Index (PSQI).

Anthropometric and body composition measurements will also be obtained, including body weight, height, body mass index (BMI), and body composition assessed by bioelectrical impedance analysis.

Fasting blood samples will be collected to evaluate selected biochemical parameters, including fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, aspartate aminotransferase (AST), alanine aminotransferase (ALT), uric acid, urea, and creatinine.

The study aims to determine whether a 12-week MIND diet-based or Mediterranean diet-based nutritional intervention is associated with changes in brain fog, perceived stress, sleep quality, anthropometric measurements, and selected biochemical parameters in young adults. Comparisons between the three study groups will be used to evaluate the potential effects of the dietary interventions.

Tipo di studio

Interventistico

Iscrizione (Stimato)

42

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 35 anni (Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Adults aged 18-35 years.
  • Willingness to participate in the study and provide written informed consent.
  • Ability and willingness to follow the assigned dietary intervention for 12 weeks.
  • Ability to complete dietary records and study questionnaires.

Exclusion Criteria:

  • Presence of chronic diseases requiring a specific medical nutrition therapy.
  • Pregnancy or breastfeeding.
  • Food allergies or intolerances that prevent adherence to the study diets.
  • Following a medically prescribed or restrictive diet.
  • Regular use of medications that may significantly affect the study outcomes.
  • Any condition that may interfere with participation in the study or adherence to the intervention.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Mind Diet Group

Participants will receive a 12-week dietary intervention based on the MIND diet.

Participants will receive a 12-week dietary intervention based on the MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet. The intervention will include individualized dietary guidance, regular nutritional counseling, dietary monitoring, and adherence assessments throughout the study period.

Sperimentale: Mediterranean Diet Group

Participants will receive a 12-week dietary intervention based on the Mediterranean diet.

Participants will receive a 12-week dietary intervention based on the Mediterranean diet. The intervention will include individualized dietary guidance, regular nutritional counseling, dietary monitoring, and adherence assessments throughout the study period.

Nessun intervento: Control Group

Participants will not receive a specific dietary intervention during the 12-week study period.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Brain Fog Scale Score
Lasso di tempo: 12 weeks

Brain fog will be assessed using the 23-item Brain Fog Scale. The total score ranges from 0 to 92. Higher scores indicate more severe brain fog symptoms and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

12 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Pittsburgh Sleep Quality Index Scores
Lasso di tempo: 12 weeks

Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The total score ranges from 0 to 21. Higher scores indicate poorer sleep quality and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

12 weeks
Change in Perceived Stress Scores
Lasso di tempo: 12 weeks

Perceived stress will be assessed using the 10-item Perceived Stress Scale (PSS-10). The total score ranges from 0 to 40. Higher scores indicate higher levels of perceived stress and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

12 weeks
Change in Fasting Blood Glucose Levels
Lasso di tempo: 12 weeks

Fasting blood glucose levels will be measured using standard biochemical laboratory methods after overnight fasting. Changes in fasting blood glucose levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Total Cholesterol Levels
Lasso di tempo: 12 weeks

Serum total cholesterol levels will be measured using standard biochemical laboratory methods. Changes in total cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Low-Density Lipoprotein (LDL) Cholesterol Levels
Lasso di tempo: 12 weeks

Serum low-density lipoprotein (LDL) cholesterol levels will be measured using standard biochemical laboratory methods. Changes in LDL cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in High-Density Lipoprotein (HDL) Cholesterol Levels
Lasso di tempo: 12 weeks

Serum high-density lipoprotein (HDL) cholesterol levels will be measured using standard biochemical laboratory methods. Changes in HDL cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Triglyceride Levels
Lasso di tempo: 12 weeks

Serum triglyceride levels will be measured using standard biochemical laboratory methods. Changes in triglyceride levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Aspartate Aminotransferase (AST) Levels
Lasso di tempo: 12 weeks

Serum aspartate aminotransferase (AST) levels will be measured using standard biochemical laboratory methods. Changes in AST levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Alanine Aminotransferase (ALT) Levels
Lasso di tempo: 12 weeks

Serum alanine aminotransferase (ALT) levels will be measured using standard biochemical laboratory methods. Changes in ALT levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Serum Uric Acid Levels
Lasso di tempo: 12 weeks

Serum uric acid levels will be measured using standard biochemical laboratory methods. Changes in serum uric acid levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Serum Urea Levels
Lasso di tempo: 12 weeks

Serum urea levels will be measured using standard biochemical laboratory methods. Changes in serum urea levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Serum Creatinine Levels
Lasso di tempo: 12 weeks

Serum creatinine levels will be measured using standard biochemical laboratory methods. Changes in serum creatinine levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Ahmet Murat Günal, PhD, Haliç University
  • Investigatore principale: Murat Baş, PhD, Acibadem University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 dicembre 2026

Completamento primario (Stimato)

1 marzo 2027

Completamento dello studio (Stimato)

1 giugno 2027

Date di iscrizione allo studio

Primo inviato

6 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

19 novembre 2026

Primo Inserito (Effettivo)

20 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

19 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be shared with other researchers due to privacy and confidentiality considerations. Data will be used solely for the purposes of this study and will be handled in accordance with applicable data protection regulations.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi